Dry eye disease in India

Dear Editor:

Recently a study from north India reported 32% prevalence of dry eye disease (DED), and based on symptoms 81% were severe DED. Another study from south India reported 1.46% DED incidence. The authors predicted that within the end of next decade, large number of urban and rural populations would have DED.

We recently published our findings of meibomian gland dysfunction. Here we present the unpublished findings of the study related to DED as a secondary analysis.

The results are summarized in Tables 1 and 2. The crude and age-adjusted prevalence rate of DED was 17.7% and 19.0% (95% CI: 15.7–22.1%), respectively. The crude and age-adjusted prevalence rate in males was 15.2% and 18.4% (95% CI: 14.1–22.8%), and in females was 20.5% and 23.3% (95% CI: 18.2–28.4%), respectively.

Our results of lower prevalence offer a different perspective. Some other Indian studies have also reported lesser prevalence rates—18.4%[4] and 15.4%[5] which are more aligned to ours, and less alarming.

All the above studies[1-3] are hospital-based, and generalization of results should be done cautiously. Studies[4,5] reporting low DE prevalence like ours, are from less urban areas than those[1,2] reporting higher prevalence. The degree of urbanization influences lifestyle, and exposure to environmental risk factors which may explain the differences. Ocular symptoms were less reported in our study. It is possible that the OSDI questionnaire that we used, and which has been designed specifically for a western population, was less suitable in our setting. Our diagnosis criteria was more stringent than others,[1] which may be a reason for the lower prevalence rate. It is also possible that DE is less uniformly distributed across India, with pockets of higher prevalence. Therefore, any extrapolation[2] to whole of India must be done with circumspection. A multi-centric study across India may provide a more representative magnitude of DED.

Financial support and sponsorship

Nil.

Table 1: Result of different Dry Eye Disease tests in 570 subjects

| DED tests                              | Number of patients (percentage) | Mean±SD (range) |
|----------------------------------------|---------------------------------|-----------------|
| Ocular Surface Disease Index score ≥13 | 140 (24.6)                     | 9±12.9 (0-83)   |
| Tear film height <0.3 mm               | 64 (11.2)                       | 0.4±0.1 (0.1-0.7) mm |
| Tear film break-up time <10 seconds(s) | 386 (67.7)                      | 8.3±3.7 (1-15) s |
| Lissamine Green stain score ≥2         | 36 (6.3)                        | 0.3±0.7 (0-4)   |
| Schirmer’s I test ≤5 mm at 5 mins      | 74 (13.0)                       | 20.2±11.1 (0-35) mm |

Table 2: Dry eye disease diagnosis (n=570)

| DED diagnosis criteria                        | Number (percentages) |
|-----------------------------------------------|----------------------|
| **TFOS DEWS II**                              |                      |
| DED: OSDI ≥13 + one of either TBUT <10 seconds or LGS ≥2 | 101 (17.7) |
| Evaporative DED: OSDI + TBUT                  | 77 (13.5)            |
| Aqueous tear deficient DED: OSDI + TBUT/LGS + Tear film height <0.3 mm | 23 (4.0) |
| **Japanese Dry Eye criteria**                 |                      |
| Probable DED: Any 2 of: OSDI ≥13 or TBUT <10 seconds or LGS ≥2 | 126 (22.1) |
| Definite DED: All 3 of OSDI ≥13 or TBUT <10 seconds or LGS ≥2 | 13 (2.3) |
| **Other combinations**                        |                      |
| OSDI ≥13 + Schirmer’s I ≤5 mm at 5 mins      | 28 (4.9)             |
| OSDI ≥13 + Schirmer’s I <10 mm at 5 mins     | 40 (7.0)             |
| Meibomian gland dysfunction                   | 272 (47.7)           |
| Symptomatic meibomian gland dysfunction (OSDI ≥13) | 71 (12.4) |
| Schirmer’s I >5 mm at 5 mins + TBUT <10 seconds but no Meibomian gland dysfunction | 148 (26.0) |
| Schirmer’s I ≤5 mm at 5 mins with Meibomian gland dysfunction | 45 (7.9) |

DED: Dry eye disease; OSDI: Ocular surface disease index®; TFOS DEWSII: Tear film & Ocular Surface Society Dry Eye Workshop II; TBUT: fluorescein tear film break-up time; LGS: lissamine green score; TFH: Tear film height
Conflicts of interest
There are no conflicts of interest.

Samrat Chatterjee, Deepshikha Agrawal, Arpit Sharma
Cornea and Anterior Segment Services, MGM Eye Institute, Raipur, Chhattisgarh, India
Correspondence to: Dr. Samrat Chatterjee, Cornea and Anterior Segment Services, MGM Eye Institute, 5th Mile, Vidhan Sabha Road, PO Mandhar, Raipur, Chhattisgarh - 493 111, India. E-mail: samrat@mgmeye.org

References
1. Tityal JS, Falera C, Kaur M, Sharma M, Sharma N. Prevalence and risk factors of dry eye disease in north India: Ocular surface disease index-based cross-sectional hospital study. Indian J Ophthalmol 2018;66:207-11.
2. Rao Donthineni P, Kammari P, Shanbag SS, Singh VS, Das VA, Basu S. Incidence, demographics, types and risk factors of dry eye disease in India: Electronic medical records driven big data analytics report I. Ocul Surf 2019;17:250-6.
3. Chatterjee S, Agrawal D, Sharma A. Meibomian gland dysfunction in a hospital-based population in central India. Cornea 2019. doi: 10.1097/ICO.0000000000002217.
4. Sahai A, Malik P. Dry eye: Prevalence and attributable risk factors in a hospital-based population. Indian J Ophthalmol 2005;53:87-91.
5. Rege A, Kulkarni V, Puthran N, Khandgave T. A clinical study on subtype-based prevalence of dry eye. J Clin Diagn Res 2013;7:2207-10.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Cite this article as: Chatterjee S, Agrawal D, Sharma A. Dry eye disease in India. Indian J Ophthalmol 2020;68:1499-500.
© 2020 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow